Skip to content
drillr.ai
Sign up

688266.SH

Suzhou Zelgen Biopharmaceuticals Co., Ltd.

SSE · Healthcare · Biotechnology · CN

CNY 87.79
−6.61%
Ask drillr

  • Oct 23, 2026, 12:07 UTC

    Zelgen announced that its investigational injectable ZG005 completed enrollment of the first participant in a Phase III trial for first-line liver cancer treatment.

    Source:

  • Oct 20, 2026, 10:32 UTC

    Zelgen announced that it received a $10 million milestone payment from AbbVie Inc. under their global strategic collaboration and license option agreement for ZG006, based on clinical-trial progress.

    Source:

  • Oct 13, 2026, 11:49 UTC

    China’s National Medical Products Administration accepted Zejing Pharmaceutical’s new drug application for its jakacitinib hydrochloride tablets to treat active ankylosing spondylitis, the drug’s third indication submitted for marketing approval.

    Source:

  • Sep 6, 2026, 07:32 UTC

    Zelgen Biopharmaceuticals announced that its self-developed injection of human thyrotropin beta (brand: Zesuning) for a new indication has been accepted for marketing application review by China's National Medical Products Administration.

    Source:

  • Aug 18, 2026, 19:54 UTC

    Zelgen Pharmaceuticals reported first-half 2026 revenue of 550 million yuan from four marketed innovative drugs, up 44.3% year-on-year.

    Source:

  • Aug 16, 2026, 13:57 UTC

    Zelgen Biopharmaceuticals disclosed H1 revenue of 1.205 billion yuan, up 220.88% year-over-year, with net profit of 640 million yuan, turning from loss to profit.

    Source:

  • Aug 16, 2026, 13:57 UTC

    Zelgen Biopharmaceuticals reached a BD collaboration with AbbVie on ZG006, recognizing 662 million yuan in technology licensing revenue, with both parties accelerating global development.

    Source:

  • Aug 12, 2026, 14:54 UTC

    Suzhou Zelgen Biopharmaceuticals submitted a listing application to the Hong Kong Stock Exchange for an IPO, with CICC as the sole sponsor.

    Source: